Markt oder Branche auswählen:
Chart-Typ:
Zeitraum:
| Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy | TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) announced new interim findings from its Phase 1b open-label proof-of-concept trial evaluating subcutaneous mezagitamab (TAK-079)... ► Artikel lesen |
| Takeda Reports Positive Long-Term Data From Phase 3 Trial Of Dengue Vaccine QDENGA | TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) on Monday reported positive seven-year results from its pivotal Phase 3 TIDES trial evaluating the company's dengue vaccine, QDENGA... ► Artikel lesen |
| Takeda Pharma H1 Net Profit Declines; Revenue Down 6.9% | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) reported first half net profit to owners of company of 112.4 billion yen, down 40.0% from prior year. Earnings... ► Artikel lesen |
| EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS) | EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)... ► Artikel lesen |
| Takeda Says HyHub And HyHub Duo Devices Now Available In U.S. To Simplify HYQVIA Infusion Process | TOKYO (dpa-AFX) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years... ► Artikel lesen |
| TetraScience Launches Scientific AI Lighthouse Program with Takeda as Founding Partner | Reimagining and replatforming science for the era of AI
BOSTON, Oct. 23, 2025 /PRNewswire/ -- TetraScience, the Scientific Data and AI Company, today launched its... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .